Metagenomi, Inc. (NASDAQ:MGX) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $16.67.

Several equities analysts have weighed in on the company. Chardan Capital restated a "buy" rating and set a $15.00 target price on shares of Metagenomi in a report on Wednesday, November 20th. HC Wainwright boosted their target price on Metagenomi from $7.00 to $14.00 and gave the stock a "buy" rating in a report on Tuesday, December 10th.

Metagenomi Trading Down 5.9 %

NASDAQ:MGX traded down $0.22 during mid-day trading on Monday, reaching $3.52. The stock had a trading volume of 938,408 shares, compared to its average volume of 618,707. The business's 50 day moving average is $2.54 and its 200 day moving average is $3.02. Metagenomi has a fifty-two week low of $1.61 and a fifty-two week high of $12.74.

Institutional Investors Weigh In On Metagenomi

Hedge funds have recently modified their holdings of the business. Rhumbline Advisers acquired a new stake in Metagenomi during the second quarter worth about $26,000. BNP Paribas Financial Markets lifted its position in shares of Metagenomi by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company's stock worth $28,000 after acquiring an additional 7,256 shares during the period. Virtu Financial LLC acquired a new stake in shares of Metagenomi during the 3rd quarter worth approximately $33,000. XTX Topco Ltd bought a new stake in shares of Metagenomi during the second quarter valued at approximately $66,000. Finally, Green Alpha Advisors LLC acquired a new position in shares of Metagenomi in the third quarter valued at $69,000.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.